RCMNY
RGNX icon

Rubric Capital Management (New York)’s Regenxbio RGNX Stock Holding History

Rubric Capital Management (New York)’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-287,467
Closed -$7.1M – 95
2022
Q2 		$7.1M Buy
+287,467
New +$7.18M 0.37% 52

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Rubric Capital Management (New York)'s RGNX Position: Q3 2022 in Review

Rubric Capital Management (New York) sold out of Regenxbio (RGNX) in Q3 2022, closing a stake of 287,467 shares — an estimated $7.1M sold.

Rubric Capital Management (New York) first reported a position in RGNX in Q2 2022 and held it in 1 quarter. The position peaked at $7.1M in Q2 2022. 183 funds tracked by Wall St. Rank hold RGNX as of Q3 2022.

  • Rubric Capital Management (New York) reported no remaining Regenxbio position as of Q3 2022 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 287,467 Regenxbio shares in Q3 2022, an estimated $7.1M.
  • Rubric Capital Management (New York) first reported a position in Regenxbio in Q2 2022 and held it in 1 quarter.
  • Rubric Capital Management (New York)'s Regenxbio position peaked at $7.1M in Q2 2022.
  • 183 funds tracked by Wall St. Rank held Regenxbio as of Q3 2022.

Based on Rubric Capital Management (New York)'s 13F filing for Q3 2022, filed 14 Nov 2022.